Fig. 5: PET imaging of [18F]OXD-2314 in rhesus macaque monkeys.
From: Ligand-based design of [18F]OXD-2314 for PET imaging in non-Alzheimer’s disease tauopathies
A Representative transverse PET summation images (0–11 min and 60–90 min) of macaque brain from baseline PET scan using [18F]OXD-2314. B Time-activity curves of standardized uptake values (SUV) in macaque (n = 1) whole brain (solid circles,
), cortex (triangles,
), and cerebellum (rings, (
) from baseline PET scan using [18F]OXD-2314 over 0–90 min. C–E Time-activity curves of SUV in macaque (n = 1) from a displacement PET experiment using [18F]OXD-2314 with unlabeled OXD-2314, (C) whole brain, (D) cortex, and (E) cerebellum. Baseline (
) and displacement ((
) PET imaging in macaque, 0–90 min. The displacing dose of unlabeled OXD-2314 (0.5 mg/kg) was administered at 10 min post-injection (indicated by arrows). No significant displacement of [18F]OXD-2314 could be detected in any brain region, as expected in animals without tau pathology.
